Exploring Three Indian Exchange Stocks With Intrinsic Value Discounts Ranging From 18.4% To 42.7%

In This Article:

The Indian stock market has experienced a slight dip of 1.3% over the past week, yet it maintains a robust annual growth of 43%, with earnings expected to grow by 16% annually. In this context, identifying stocks that are undervalued relative to their intrinsic value can be particularly compelling for investors looking for potential opportunities in a growing market.

Top 10 Undervalued Stocks Based On Cash Flows In India

Name

Current Price

Fair Value (Est)

Discount (Est)

HEG (NSEI:HEG)

₹2045.25

₹3292.68

37.9%

IOL Chemicals and Pharmaceuticals (BSE:524164)

₹403.15

₹636.71

36.7%

Updater Services (NSEI:UDS)

₹309.35

₹538.16

42.5%

Vedanta (NSEI:VEDL)

₹439.80

₹717.96

38.7%

Rajesh Exports (NSEI:RAJESHEXPO)

₹300.90

₹506.76

40.6%

Mahindra Logistics (NSEI:MAHLOG)

₹512.70

₹901.81

43.1%

Strides Pharma Science (NSEI:STAR)

₹952.70

₹1664.05

42.7%

Delhivery (NSEI:DELHIVERY)

₹374.30

₹740.20

49.4%

Godrej Properties (NSEI:GODREJPROP)

₹3245.75

₹5592.14

42%

PVR INOX (NSEI:PVRINOX)

₹1402.50

₹2538.40

44.7%

Click here to see the full list of 20 stocks from our Undervalued Indian Stocks Based On Cash Flows screener.

Let's dive into some prime choices out of from the screener.

Dalmia Bharat

Overview: Dalmia Bharat Limited, along with its subsidiaries, specializes in producing and marketing clinker and cement products mainly in India, boasting a market capitalization of approximately ₹341.09 billion.

Operations: The company primarily generates revenue from the production and sale of clinker and cement products in India.

Estimated Discount To Fair Value: 18.4%

Dalmia Bharat, trading at ₹1818.7, is perceived as undervalued against a fair value estimate of ₹2230.13, marking an 18.4% discrepancy. Despite slower revenue growth projections at 10.8% annually compared to the broader market's 9.6%, its earnings are expected to surge by approximately 21.33% per year over the next three years, outpacing the Indian market forecast of 15.9%. However, its dividend yield of 0.49% raises concerns over sustainability due to inadequate coverage by free cash flows and a modest forecasted Return on Equity (ROE) of only around 7%.

NSEI:DALBHARAT Discounted Cash Flow as at Jul 2024
NSEI:DALBHARAT Discounted Cash Flow as at Jul 2024

Strides Pharma Science

Overview: Strides Pharma Science Limited is a pharmaceutical company that develops, manufactures, and sells products across multiple continents including Africa, Australia, North America, Europe, and Asia with a market capitalization of approximately ₹87.57 billion.

Operations: The company generates ₹40.51 billion from its pharmaceutical business, excluding the bio-pharmaceutical segment.